Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Acute liver failure associated with Fructus Psoraleae: a case report and literature review.

  • 2019-04-11
  • BMC complementary and alternative medicine 19(1)
    • Ang Li
    • Minhong Gao
    • Na Zhao
    • Ping Li
    • Jinguo Zhu
    • Wenfei Li

Study Design

Type
Review
Population
a 53-year-old woman with vitiligo
Methods
treated with Qubaibabuqi tablets for approximately 7 months
Duration
approximately 7 months

Background

Fructus Psoraleae is the seed of Psoralea corylifolia Linn. Fructus Psoraleae has been shown to be effective in treating some skin diseases, such as vitiligo. As a main ingredient in five types of herbs in the Qubaibabuqi tablet formula, Fructus Psoraleae plays an important role in the treatment of vitiligo. Fructus Psoraleae has potential hepatotoxicity, thus Qubaibabuqi tablets also have potential liver toxicity.

Case presentation

A 53-year-old woman who was diagnosed with vitiligo in September 2017 was treated with Qubaibabuqi tablets. After approximately 7 months of treatment, the patient developed a severe, diffuse yellow staining of the skin and sclera in March 2018. On admission, she was diagnosed with acute cholestatic hepatitis associated with Fructus Psoraleae. Despite receiving active treatment, her condition rapidly deteriorated and she died 5 days later due to acute liver failure and multiple organ dysfunction. To the best of our knowledge, there are only six reported cases of liver injury associated with Fructus Psoraleae described in the English language literature; however, cases of acute liver failure associated with the use of Fructus Psoraleae have not been described.

Conclusion

As a main ingredient in the Qubaibabuqi tablet formula, Fructus Psoraleae has potential hepatotoxicity. This potentially fatal adverse effect should be considered when physicians prescribe Qubaibabuqi tablets.

Research Insights

    Back to top